Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. - Wikidata - thesis-toulmin - TriplyDB

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.

http://www.wikidata.org/entity/Q34218584

about

Alzheimer mechanisms and therapeutic strategies Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease Early Dementia Screening Mouse models of frontotemporal dementia Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets Therapeutic and diagnostic challenges for frontotemporal dementia The role of tau in neurodegenerative diseases and its potential as a therapeutic target Tau and tauopathies Tau Biology and Tau-Directed Therapies for Alzheimer's Disease The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy Aβ-mediated spine changes in the hippocampus are microtubule-dependent and can be reversed by a subnanomolar concentration of the microtubule-stabilizing agent epothilone D Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies Altered microtubule dynamics and vesicular transport in mouse and human MeCP2-deficient astrocytes.The Dynamics and Turnover of Tau Aggregates in Cultured Cells: INSIGHTS INTO THERAPIES FOR TAUOPATHIES.Low dose tubulin-binding drugs rescue peroxisome trafficking deficit in patient-derived stem cells in Hereditary Spastic Paraplegia.Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases.Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease Direct interaction between selenoprotein P and tubulin Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.Motor and cognitive deficits in aged tau knockout mice in two background strains.The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus.The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles.In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy.A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function.Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration.Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease.Rescue of tau-induced synaptic transmission pathology by paclitaxel.Advances in tau-based drug discovery.Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation.Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy The many faces of tau The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

P2860

Q22252311-E8F53BFB-18D0-4B0C-BB54-E6909CD4770C Q26739412-4E786DAF-5B9E-4107-A4BC-D648374706FF Q26770171-5837A3EB-D38C-4D1B-9632-A8E34BB29C63 Q26829009-7CEAC146-A1FC-445A-9F08-97714394F5FB Q26859305-CC39EDBD-F6F0-497B-8C71-BC4D64123F8D Q26861683-2A1DD926-99E7-472A-A4DA-974F97281809 Q26865234-2F36C5D6-11C7-44DE-8BB5-82580E226AB3 Q26865654-624EDDF2-71B9-4CC4-BADA-70ED09B033A0 Q26998919-74B4AE1D-9033-4BA7-95CA-C57BF7EC810A Q27005032-4EBCBE77-FE44-433E-83F5-5351C7C4A652 Q27027415-27FDA0DB-ED71-441B-9B52-EFFD1603C0D3 Q28071398-CE934A25-C31D-4C02-95E0-9E426B710218 Q28119005-19E29236-4C7D-416D-9191-27810489AAA7 Q30355359-9DCA6D02-BE34-436D-9927-C68E55A07FE4 Q30539763-0D45311B-D3F0-4213-BA7D-47CA0E8B891F Q30540857-2407EA9A-BE31-4A66-8B92-3A0E45FBEA27 Q30669674-EBF34283-4492-4E4E-A538-BB53603504B4 Q30692336-432F6D1B-2E59-4D07-9098-E5B99BFAAFEB Q30780758-A6C92181-55E2-4A6C-ABD3-94584E307CE3 Q33757254-DA71987B-2E94-4820-BE19-01E0F4FE1104 Q33832795-4BC43923-7A21-476B-811C-DF2EAA971162 Q33887379-4B0B8D79-45B6-4676-8093-509EA5BD19E8 Q33907716-D395A31E-4B64-428D-A2B4-4DA70A50C367 Q33951935-C6C94626-BB94-485E-94F2-86E1AB5EEE88 Q34077327-67ECAED1-971B-4244-A530-898485867650 Q34477111-1A6D6332-7B6D-4340-895B-9BCF963411CD Q34525286-66595DCA-201A-452A-9137-F54AAE61A6F3 Q34587678-2E1E4FE7-686C-4FB4-B0AC-62C5683C1C22 Q34869120-023AA5ED-D63B-4BAF-BB0E-781A93F28B34 Q35002449-BB460AC0-3ADF-440D-BDC0-599738503849 Q35006348-54783C06-BEA4-4D27-8779-C47417A05848 Q35055486-E745CC38-37DE-4D6D-80C6-6A6350D0989E Q35064974-E0B36A38-3E3B-4F1C-996A-EF8B608E678D Q35103703-B70DD3BA-1867-4DD3-85D5-E2A5B29FAD8D Q35321539-A0E33560-706B-4151-9013-B9D19E29C7DF Q35565682-9DD8FC94-D3A7-451A-B3EF-BEAB049DCB89 Q35590867-B00D5E4A-34CC-4885-A605-614010EDC872 Q35870359-14F45D52-A6CA-42FD-9CE8-72A72A90C494 Q35875920-83065615-153F-4CBC-96DE-D7AFC3726269 Q36012200-4397450F-8878-45A0-92D3-A58A9BDF7CA3

P2860

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.

http://www.wikidata.org/entity/Q34218584

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@ast

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@en

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@nl

type

label

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@ast

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@en

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@nl

prefLabel

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@ast

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@en

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@nl

P1433

Q34218584-61CE28D9-A02D-4D7E-9AAB-EAC1FF2306FB

P1476

Q34218584-21521C4B-8993-4471-BFE8-52B7A218C6FF

P2093

Q34218584-0A0EBCCC-6D25-4D99-9D5B-E24231348BE3

Q34218584-0AC57D77-0501-4EBA-AF36-0617297586C0

Q34218584-0E77B2E1-39BE-4DF6-A055-95CFFE0F0742

Q34218584-1D949EB9-4228-4CFB-900E-7F4DA885A549

Q34218584-458D250A-EEBC-4892-BB0C-14888FB42ACA

Q34218584-6AA3D7A2-3938-45A6-B746-93BD79058065

Q34218584-AF401868-B215-4ACB-AE6E-540406EF601E

Q34218584-CBDD2C1D-6CB6-4DC5-9308-749312FB1416

Q34218584-CF2453DC-FCEB-4172-8DDE-257006BD066D

Q34218584-DE50441E-4E00-467C-A5E8-3B830ACEA2B5

P2860

Q34218584-08273243-91AE-4B8F-8495-47CCC382BF19

Q34218584-14B07657-4A02-4BBC-A933-BF99BA0277CB

Q34218584-16FDF5F7-63FB-4125-93A2-37361A49735E

Q34218584-1B3C3374-6851-40D1-8E4F-976364EDFE3B

Q34218584-209B5E23-062F-483E-9624-3883C866CAFD

Q34218584-257E8182-B211-4056-ACE8-97A6FFBC394D

Q34218584-2B719DD6-1AF9-4B36-A88C-17CEC1014DD3

Q34218584-2D1C8B8B-32D9-4339-9F25-CCADDC0E015A

Q34218584-32F42C10-0C4B-4CD2-A23A-74CA0EF3994D

Q34218584-37942A6A-2C94-4D12-BA25-2ECE3A790551

P304

Q34218584-F32C73DF-EA6B-4206-AE42-BF2654C6C298

P31

Q34218584-4DBF07C4-FA82-4D98-AB0E-13F777C6B248

P356

Q34218584-2F755644-BADC-4A89-BD4D-22EA60E3CB06

P407

Q34218584-3DAC9307-A923-4408-BFC8-52E54F2E49B0

P433

Q34218584-2C19D895-92EB-42D6-99D9-042DB69D5AC8

P478

Q34218584-455D4042-6D39-48DD-B94C-CB741A392911

P50

Q34218584-CEEE17F5-1987-4042-95B5-931285C43C22

P577

Q34218584-D50ADA99-71EE-41D5-A7A7-A02F6F14AD7C

P698

Q34218584-3007AA38-CBBF-4450-B1B2-A62CDEFCBC2C

P932

Q34218584-589C9A9E-E2E9-4F1C-9E2F-424D1DBAE685

P356

JNEUROSCI.3059-10.2010

P1433

Journal of Neuroscience

P1476

Epothilone D improves microtub ...... enic mouse model of tauopathy.

@en

P2093

Amos B Smith

http://www.w3.org/2001/XMLSchema#string

Anne-Marie L Hogan

http://www.w3.org/2001/XMLSchema#string

Bin Zhang

http://www.w3.org/2001/XMLSchema#string

Carlo Ballatore

http://www.w3.org/2001/XMLSchema#string

Jenna Carroll

http://www.w3.org/2001/XMLSchema#string

Justin S Potuzak

http://www.w3.org/2001/XMLSchema#string

Kurt R Brunden

http://www.w3.org/2001/XMLSchema#string

Michael J James

http://www.w3.org/2001/XMLSchema#string

Michiyo Iba

http://www.w3.org/2001/XMLSchema#string

Sharon X Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model

Random-effects models for longitudinal data

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Neurodegenerative tauopathies

The distribution of tau in the mammalian central nervous system

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.

Models for longitudinal data: a generalized estimating equation approach.

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

P304

13861-13866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.3059-10.2010

http://www.w3.org/2001/XMLSchema#string

P407

P433

41

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

John Q. Trojanowski

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20943926

http://www.w3.org/2001/XMLSchema#string

P932

2958430

http://www.w3.org/2001/XMLSchema#string